ライフサイエンスコーパス: drug delivery

1 le barriers in sequence to achieve cytosolic drug delivery.

2 nd transport considerations for intratumoral drug delivery.

3 rials, biomaterials, and pharmaceutical oral drug delivery.

4 ing gas storage, separations, catalysis, and drug delivery.

5 r treating transport disorders and improving drug delivery.

6 y, mechanism and challenges of nose-to-brain drug delivery.

7 nanoclusters (MUA-Au NCs) for tumor-targeted drug delivery.

8 eads to poor tissue perfusion and cytostatic drug delivery.

9 molecules, and surface functionalization for drug delivery.

10 damage (hemolysis) and mechanoporation-based drug delivery.

11 ing vasoconstriction, and limiting blood and drug delivery.

12 es assuring precision and reproducibility of drug delivery.

13 argeting liposome nanocarriers for placental drug delivery.

14 uding immunotherapy, tissue engineering, and drug delivery.

15 evaluating nanoparticles for intra-articular drug delivery.

16 acy of locally-delivered Scl-Ab for targeted drug delivery.

17 t, for targeted pulmonary inhalation aerosol drug delivery.

18 ned process for productive intracellular ASO drug delivery.

19 dly suitable for tumour-specific imaging and drug delivery.

20 development issues and knowledge gaps in SC drug delivery.

21 , and bacteria have been utilized to advance drug delivery.

22 ) as counteractive measures for intraluminal drug delivery.

23 itive triblock copolymer for extended ocular drug delivery.

24 e it worthwhile to reconsider their role for drug delivery.

25 y processes require varied approaches to CNS drug delivery.

26 ight into inhalation strategies for targeted drug delivery.

27 l stimuli-responsive microneedle patches for drug delivery.

28 ijack this natural process for intracellular drug delivery.

29 e, molecular separations, energy storage and drug delivery.

30 catalysis and separation to gas storage and drug delivery.

31 e range of biomedical applications including drug delivery.

32 rs and can be exploited for both imaging and drug delivery.

33 m, in particular for medical diagnostics and drug delivery.

34 A) and loaded FGF on the PXDDA for sustained drug delivery.

35 ons in such areas of tissue regeneration and drug delivery.

36 ender a possible anchor for biofilm-targeted drug delivery.

37 al drug powder to elicit multi-day sustained drug delivery.

38 cancer treatment by using EVs as devices for drug delivery.

39 ost MOFs for diverse applications, including drug delivery.

40 nges to the enhancement of immunosuppressive drug delivery.

41 d can be used for tumor-targeted imaging and drug delivery.

42 unction with age and a strategy for enhanced drug delivery.

43 nalized polymers for protein conjugation and drug delivery.

44 -based biomaterials in the realm of advanced drug delivery.

45 d healing treatments by providing controlled drug delivery.

46 r to achieve noninvasive and localized brain drug delivery.

47 imuli-responsive in situ nasal gel for brain drug delivery.

48 hat may have relevance to BBB regulation and drug delivery.

49 specific platform for tissue engineering and drug delivery.

50 ntal exposure and potential for nanoparticle drug delivery.

51 widely considered as an optimal material for drug delivery.

52 en can be strategically exploited to enhance drug delivery.

53 materials used for regenerative medicine and drug delivery.

54 ithin human facial skin and confirm accurate drug delivery, a selective visualization method to monit

55 me approaches for brain targeting, including drug delivery across BBB and direct nose-to-brain drug d

56 cellular and physical strategies to improve drug delivery across the BBB and BTB and discuss their i

57 Drug delivery across the blood-brain barrier (BBB) remai

58 Besides sustained drug delivery, AFL-assisted powder reservoir patch deliv

59 to boost the fish immune system and also as drug delivery agents.

60 delivery across BBB and direct nose-to-brain drug delivery along with the current global status of sp

61 n of microswimmers is essential for targeted drug delivery and applications of micro/nanomachines in

62 have important clinical implications for CNS drug delivery and clearance of CNS waste products, inclu

63 umor vascularization, which in turn enhances drug delivery and efficacy of cytotoxic gemcitabine chem

64 tical ingredient (API) allows for evaluating drug delivery and efficacy, which is necessary to ensure

65 alteration in tumor blood flow could augment drug delivery and improve antitumor responses in a regio

66 , their unique applications in the fields of drug delivery and medical device fabrication, material e

67 ence the performance of bio/sensing, improve drug delivery and photo/thermal therapy as well as affec

68 f therapy for biomedical application such as drug delivery and regenerative medicine.

69 in cells with mutated EGFR resulted in poor drug delivery and retarded growth in vivo but not in vit

70 The efficiency of drug delivery and sensory perception is intertwined with

71 platform was used to investigate MB enhanced drug delivery and showed that co-delivery of 3 muM doxor

72 late the physiological barriers for enhanced drug delivery and significantly improve the tumor penetr

73 logical barriers that hinder tissue-specific drug delivery and strategies to overcome them.

74 e crucial role of the biomolecular corona in drug delivery and the release efficacy of nanocarriers d

75 patible IDPs, with potential applications in drug delivery and tissue engineering.

76 er (BBB) properties are impediments to brain drug delivery, and brain vascular dysfunction accompanie

77 carriers for diagnostic imaging, vaccine and drug delivery, and combined diagnosis/therapy (theranost

78 m, primary mechanisms of therapeutic action, drug delivery, and imaging potential.

79 ariety of processes, including phagocytosis, drug delivery, and the effects of small microplastics an

80 tensive applications in filtration, sensing, drug delivery, and tissue engineering that often require

81 -BBB opening protocols into a wider range of drug delivery applications and may even lead to new type

82 been investigated and exploited for targeted drug delivery applications in the context of cancers and

83 a broad range of non-cutaneous and cutaneous drug delivery applications, including multicomponent vac

84 lobal health and developed world long-acting drug delivery applications.

85 re designed for regenerative engineering and drug delivery applications.

86 ign of more tailored supramolecular gels for drug delivery applications.

87 ng groups/catalysts for chemical biology and drug-delivery applications.

88 This innovative drug delivery approach could transform the treatment of

89 in tumour volume suggests that the proposed drug delivery approach has the potential to be an effect

90 this review, we discuss nanotechnology-based drug delivery approaches for acute kidney injury, chroni

91 ur study builds upon previous chitosan-based drug delivery approaches, and demonstrates a novel, oral

92 ic strategy of using ultrasound for improved drug delivery are summarized with the special focus on c

93 application in a plethora of areas including drug delivery, artificial muscles, etc.

94 ng provides a stable nano-platform for chemo-drug delivery as well as an efficient method to solubili

95 th various functions such as for imaging and drug delivery as well as in combination with other treat

96 emerging as leading candidates for nanoscale drug delivery, as a consequence of their high drug capac

97 ials for applications such as bioimaging and drug delivery, as well as for assessing engineered nanom

98 facilitating immune responses and overcoming drug delivery barriers.

99 been used as probes for protein tracking and drug delivery because of their ability to carry therapeu

100 g conjugates are promising as strategies for drug delivery, because of their high drug loading capaci

101 The applicability of this approach for drug delivery, bioimaging, and cell targeting was also d

102 portant physical process with application to drug delivery, biomedical imaging, separation, and mixin

103 e of bio applications, such as biomaterials, drug delivery, biomedicine, biotherapy and bioelectronic

104 rapy (RT), multimodal imaging, theranostics, drug delivery, biosensing, and tissue engineering.

105 ibers in wound healing, tissue regeneration, drug delivery, biosensors, and other high-tech applicati

106 dical fields, such as antimicrobial therapy, drug delivery, biosensors, nerve regeneration, and tissu

107 Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been in

108 While efforts to perform targeted drug delivery by engineered nanoparticles have shown som

109 Drug delivery by topical application has higher patient

110 on, tumor vascularization, and corresponding drug delivery by using ferumoxytol-enhanced MRI and macr

111 onally, in using an ultrasound (US) trigger, drug delivery can be localised to the tumour, thus reduc

112 f@pSiNP on cell migration, together with the drug-delivery capability of pSiNP, could potentially off

113 s and devices for biomedical applications as drug delivery carriers, in bioelectronics, and tissue en

114 tial applications in biological sciences for drug delivery, cell manipulation and tissue engineering.

115 These novel formulations will address drug delivery challenges and have great potential to imp

116 te of drug administration like nose-to-brain drug delivery could overcome the hurdle and improves the

117 apeutics and holds promise for new drugs and drug delivery designs.

118 ir use in a range of applications, including drug delivery, detoxification, immune modulation, and ti

119 omputational modeling of the electrophoretic drug delivery device is carried out.

120 for development of various types of targeted drug delivery devices for early prognosis and successful

121 Recent advances in optical coding, drug delivery, diagnostics, tissue engineering, shear-in

122 of the more complex biological barriers for drug delivery due to the combined effect of short contac

123 ze the newborn infant, appropriate routes of drug delivery during resuscitation, and consideration of

124 An increase in drug delivery efficiency compared to a standard DEB was

125 Despite their benefits, DEBs have poor drug delivery efficiency due to short balloon inflation

126 To increase drug delivery efficiency, a microneedle DEB (MNDEB) was

127 cles for mechanosensing, tissue engineering, drug delivery, energy storage, and displays.

128 y extends the capabilities in targeted cargo/drug delivery, environmental remediation, and other pote

129 The field of brain drug delivery faces many challenges that hinder developm

130 xt-generation approaches in nanomedicine and drug delivery, focusing on preclinical advancements in n

131 and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-ba

132 c chips (lab-on-a-paper) for diagnostics and drug delivery for biomedical applications.

133 The superior drug delivery/gene transfection/genome-editing efficienc

134 Nanoparticle drug delivery has many advantages over small molecule th

135 only used synthetic polymers in the field of drug delivery have been related to problems regarding to

136 targeting strategies to enable site-specific drug delivery holds promise in reducing off-target effec

137 Thus, subcellular drug-delivery holds promise as a means to reduce off-tar

138 the challenges posed by the BBB and BTB for drug delivery, how multiple cell types dictate BBB funct

139 , clinical translation is limited by several drug delivery hurdles including renal clearance, phagocy

140 ied ways, they can begin to be optimized for drug delivery in a more personalized manner, entering th

141 vidence for the ability of MRgFUS to enhance drug delivery in a mouse model of DIPG.

142 ia-based nanotheranostics and AMF-stimulated drug delivery in biomedical applications.

143 o several targeting strategies that modulate drug delivery in both the preclinical and clinical setti

144 ensures cell viability and enables targeted drug delivery in cancer therapy.

145 ing some long-standing challenges with local drug delivery in cancer treatment and may serve as a via

146 (1) nanotechnology, which has revolutionized drug delivery in desmoplastic tissues, harnessing physio

147 DNR antagonists can be repurposed to improve drug delivery in VEGFA-secreting tumors, which normally

148 s seriously hampered by multiple barriers to drug delivery, including severe destabilizing effects in

149 from phagolysosomal destruction and limited drug delivery into infected cells.

150 e also initiating enhanced extravasation and drug delivery into target tissues.

151 mpound's plasma half-life and thus assist in drug delivery into tumors.

152 Nanocarrier-mediated drug delivery is a promising strategy to maximize the po

153 ificant challenges remaining in the field of drug delivery is insufficient targeting of diseased tiss

154 vantages of the fields of drug discovery and drug delivery is invaluable for the advancement of drug

155 and target CCR2-expressing cancer cells for drug delivery, KLAK-MCP-1 micelles consisting of a CCR2-

156 imaging (MRI), magnetic targeting, gene and drug delivery, magnetic hyperthermia for tumor treatment

157 Nanomaterial-based drug delivery may overcome these limitations by increasi

158 ovesicles (CIMVs) were shown to be effective drug delivery mediators.

159 e a broad range of potential applications in drug delivery, medical devices and diagnostics.

160 s tackled several limitations of traditional drug delivery methods for both cancer detection (e.g., u

161 iamagnetic objects (e.g., polystyrene beads, drug delivery microcapsules, and living cells) are patte

162 pies, including an approximately 70-nm model drug delivery nanoparticle (DDNP) to target TAM, and an

163 chemical classes and developments in ocular drug delivery (ODD) are presented.

164 remain until now the most used materials in drug delivery of active pharmaceutical ingredients (APIs

165 hanced tissue distribution and intracellular drug delivery of molecules, nanoparticles, and other the

166 lecular corona on the controlled release and drug delivery of nanocarriers will help researchers desi

167 Buccal drug delivery offers a potential non-invasive means of d

168 goal of this study was to characterize FUSIN drug delivery outcome in mice with regard to its depende

169 r strategizing pulmonary surfactant (PS) for drug delivery over the respiratory air-liquid interface:

170 rchers toward the cutting edge of controlled drug delivery, particularly magnetic particle targeting.

171 -driven reactions, including light-triggered drug delivery, photodynamic therapy, and photocatalysis.

172 enerated metal NPs represent a biocompatible drug delivery platform for chemotherapy resistant tumor

173 ant vesicles (NISV) have long been used as a drug delivery platform for cutaneous applications and ha

174 -forming microneedle arrays as a transdermal drug delivery platform for ESK and supports moving to in

175 A charge-based cartilage homing drug delivery platform like this can elicit disease modi

176 potential of glucosamine-decorated NISV as a drug delivery platform with wider potential applications

177 reproducible manner, serving as screening or drug delivery platforms.

178 rivatives applicable for controlled/targeted drug delivery purposes.

179 Drug delivery-related research involving polysaccharides

180 Intravenous injection is the least invasive drug delivery route to the brain, but has been severely

181 of drugs is one of the most patient-friendly drug delivery routes.

182 The unmet clinical need which drug delivery seeks to address is discussed with referen

183 As a systemic drug delivery source, opioids leave patients at high ris

184 es, in part, due to the absence of effective drug delivery strategies.

185 on, particularly nerve guidance conduits and drug delivery strategies.

186 This clinically viable drug delivery strategy can be applied not only to peptid

187 onstructed a natural-lipid (NL) nanoparticle drug delivery system (NP-DDS) to encapsulate 6-shogaol a

188 st and smart "all-in-one" nanoparticle-based drug delivery system capable of overcoming biological ba

189 PSMA peptide-targeted EMs can be a promising drug delivery system for advanced PC.

190 Our aim was to develop a drug delivery system for angiotensin-(1-9).

191 The application of nanocarriers as drug delivery system for chemotherapeutic drugs has beco

192 vel nucleoside-based supramolecular gel as a drug delivery system for proteins with different propert

193 Thus, they represent a potent drug delivery system for the application in a variety of

194 orward for developing a locally administered drug delivery system for treating DCIS, for which no pri

195 ligands within liposomes, a well-established drug delivery system that enables payload stability and

196 s (LTSLs) are a promising stimuli-responsive drug delivery system that rapidly releases DOX in respon

197 edles (MNs) have been proposed as a suitable drug delivery system to facilitate intradermal delivery

198 lized delivery of rapamycin via a biomimetic drug delivery system, it is possible to reduce vascular

199 e correct administration procedure, suitable drug delivery system, selection of effective and safe do

200 jective of this study was to develop a novel drug delivery system, solid lipid nanoparticle (SLN), ca

201 rats using a modified vibrating mesh aerosol drug delivery system.

202 lf-powered on-skin iontophoretic transdermal drug-delivery system is developed as an on-skin chemical

203 This study aimed to fabricate an efficient drug-delivery system to reduce the undesirable side effe

204 Over the last several decades, numerous drug delivery systems (DDS) have been developed in order

205 Spurred by newly developed drug delivery systems (DDSs), side effects of cancer che

206 carriers are one kind of these newly emerged drug delivery systems (DDSs), which enable drugs to rapi

207 he next generation of bacteriocin nano-sized drug delivery systems (Nano-DDS).

208 (NP) entries as core components of nanoscale drug delivery systems (NDDSs) by making use of analytica

209 Functionalized drug delivery systems against malignant lung metastasis

210 Nano-fabricated smart drug delivery systems and implantable drug loaded biomat

211 (i.e. biosensors, microfluidic bioreactors, drug delivery systems and Lab-On-Chip).

212 s, such as new symptomatic drugs, innovative drug delivery systems and novel surgical interventions g

213 e employed various free radical-incorporated drug delivery systems as an approach to target biofilm f

214 Transdermal drug delivery systems as films not only avoids first-pas

215 Drug delivery systems based on electrospun fibers have b

216 ectrospun nanofibers based "fast dissolving" drug delivery systems by employing variety of polymers,

217 The advanced drug delivery systems can improve the macrophage-based t

218 In this study, electrospun membrane drug delivery systems consisting of the antibiotic cipro

219 e and commonly used therapy, introduce local drug delivery systems currently on the market or in the

220 Drug delivery systems featuring first-order release kine

221 ents will enable discovery of more effective drug delivery systems for brain.

222 disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

223 ercome this barrier, nanoparticle (NP) based drug delivery systems have been reported.

224 Cell-based drug delivery systems have generated an increasing inter

225 The electrospun nanofiber based drug delivery systems have shown tremendous advancements

226 Zero-order drug delivery systems have the potential to overcome the

227 Targeting drug delivery systems is crucial to reducing the side ef

228 limitations of retinoids, the development of drug delivery systems offers several advantages for clin

229 Injectable, long-acting drug delivery systems provide effective drug concentrati

230 rowing use of agarose-based biomaterials for drug delivery systems resulted in rapid growth in the nu

231 , thereby contributing to the development of drug delivery systems satisfying clinical requirements.

232 Overall, implementation of local drug delivery systems such as this could reduce the need

233 eability may afford opportunities to develop drug delivery systems to improve efficacy and reduce tox

234 MCM-41, for prolonged release of atenolol in drug delivery systems was investigated both experimental

235 there is an urgent need to develop improved drug delivery systems which have potential to cross impa

236 , have led to a rapidly increasing number of drug delivery systems with potential for spatiotemporall

237 Micelles, as a class of drug delivery systems, are underrepresented among United

238 world bioelectronics applications, including drug delivery systems, biosensing and electrical modulat

239 neering and integration with biomaterials or drug delivery systems, is examined.

240 Local drug delivery systems, such as in situ forming implants

241 ential to provide a new level of control for drug delivery systems, tumor detection markers, biosenso

242 valuable strategy for the development of new drug delivery systems.

243 engineering, development of microarrays, and drug delivery systems.

244 3D printed drug products and nanofiber-based drug delivery systems.

245 rs design safer and more efficient nanobased drug delivery systems.

246 ach to fabricate bespoke medical devices and drug delivery systems.

247 ation of classical dosage forms and advanced drug delivery systems.

248 in interactions and the development of novel drug delivery systems.

249 ecent advances for the development of ocular drug delivery systems.

250 o improve the poor clinical success of local drug delivery systems.

251 unities for the application of nano targeted drug-delivery systems (Nano-TDDS) in cancer therapy.

252 Self-powered drug-delivery systems based on conductive polymers (CPs)

253 putational modeling of nanoparticle-mediated drug delivery targeting tumor vasculature coupled with n

254 However, numerous challenges remain, and drug delivery technology is underutilized in some applic

255 After 4 weeks of drug delivery, the first molar on each side of the upper

256 Despite recent advances in drug delivery, the targeted treatment of unhealthy cells

257 icroenvironment (TME), and profoundly affect drug delivery, therapeutic efficacy and the emergence of

258 In fact, drug delivery to brain remained a challenge in the treat

259 important physiological barriers to improve drug delivery to brain tumors.

260 e with cell membranes has been exploited for drug delivery to carry impermeable cargo into cells, but

261 Targeted drug delivery to joint tissues like cartilage remains a

262 ntal importance to applications ranging from drug delivery to microfluidics and from ablation to fabr

263 Efficient and specific drug delivery to the BM is an unmet need.

264 Drug delivery to the brain always remains a challenging

265 e receptors (nAChRs), termed (D)CDX, enables drug delivery to the brain when incorporated into liposo

266 novel technique for noninvasive stereotactic drug delivery to the brain with temporal specificity cou

267 method has been used for decades to improve drug delivery to the brain.

268 Targeted drug delivery to the endothelium has the potential to ge

269 Therefore, drug delivery to the kidneys faces significant difficult

270 particles, CBSA/siS100A4@Exosome) to improve drug delivery to the lung PMN.

271 d effective approaches for magnetic particle drug delivery to the lung, all supporting improved lung

272 el layer allows for therapeutically relevant drug delivery to the posterior segment of the eyeball in

273 ninvasive, localized and temporally specific drug delivery to the rat brain.

274 Drug delivery to the skin is highly constrained by the s

275 cargo, EVs may provide an effective mean of drug delivery to the target site.

276 abine and thus offers the potential to image drug delivery to tumors.

277 echnological advances and the development of drug delivery tools are also discussed.

278 hallenges, and future of ultrasound-mediated drug delivery towards clinical translation.

279 Further, the recent advances in drug delivery using M1 macrophages, macrophage-derived e

280 Transdermal drug delivery using spring-powered jet injection has bee

281 serum albumin (HSA) as a solubilising agent/drug delivery vehicle for pulmonary administration of an

282 nstrated by the discovery of a candidate CNS drug delivery vehicle ready for further optimization and

283 ity and efficiency of the nanostructure as a drug delivery vehicle.

284 Nanomaterial-based drug delivery vehicles are able to deliver therapeutics

285 Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield

286 yer-by-layer nanoparticles (NPs) are modular drug delivery vehicles that incorporate multiple functio

287 Design of drug delivery vehicles, cell and tissue matrices, and im

288 heir potential utility as nanobioreactors or drug delivery vehicles.

289 ate targeting mechanisms, and can be used as drug-delivery vehicles to increase the efficiency with w

290 l barriers that are impermeable to synthetic drug-delivery vehicles.

291 nisms, for applications as protocells, or as drug-delivery vehicles.

292 CDPs) have drawn recent interest as drugs or drug-delivery vehicles.

293 increase HER2-positive tumor cell selective drug delivery, we optimized the two most important desig

294 bone, their specificities and capacities for drug delivery were significantly inferior to subsequent

295 n biomedical applications such as controlled drug delivery where intravenous injection of the particl

296 ed immune modulation and macrophage-mediated drug delivery, which will further enhance current tumor

297 monitor targetability, pharmacokinetics, and drug delivery, while also showing therapeutic efficacy i

298 hotoacoustic imaging (PAI), and image-guided drug delivery with a tunable drug release capacity.

299 g recognition as a new modality for targeted drug delivery with improved efficacy and reduced side ef

300 Drug delivery with targeted nanoparticles have been show